Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin

Ertugliflozin, an inhibitor of sodium‐glucose cotransporter 2, is approved in the United States and European Union for the treatment of type 2 diabetes in adults, both as monotherapy and as part of fixed‐dose combination (FDC) therapies with either sitagliptin or immediate‐release metformin. The eff...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Pharmacol Drug Dev
Päätekijät: Sahasrabudhe, Vaishali, Fediuk, Daryl J., Matschke, Kyle, Shi, Haihong, Liang, Yali, Hickman, Anne, Bass, Almasa, Terra, Steven G., Zhou, Susan, Krishna, Rajesh, Dawra, Vikas K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2018
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6618047/
https://ncbi.nlm.nih.gov/pubmed/30427588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.629
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia